Diagnostic Values of Galectin-3, Soluble ST2 and BNP in Predicting the Clinical Outcome of ST-Segment Elevation Myocardial Infarction Patients

Study Overview
=================
Brief Summary
-----------------
An acute ST-elevation myocardial infarction occurs due to occlusion of one or more coronary arteries, causing transmural myocardial ischemia which in turn results in myocardial injury or necrosis. Acute myocardial infarction (AMI) may lead to the development of heart failure (HF). Accessible diagnostic tools commonly used in HF such as natriuretic peptides and (NYHA) classiﬁcation reﬂect already overt clinical HF. Troponin and creatine kinase reﬂect myocardial damage, but their usefulness in predicting long-term LVR is limited. Recent guidelines on HF management stressed that HF onset may be delayed or prevented through certain Interventions, such as pharmacotherapy ,post infarction rehabilitation, or modiﬁcation of HF risk factors. Therefore, it is important to identify potential markers, which would be more informative of HF preclinical stages to recognize patients with an increased risk of HF onset, and to start treatment in advance (1) Gal-3 participates in inﬂammation and pro ﬁbrotic pathways, while sST2 is a biomarker of inﬂammation, cardiac mechanical strain, and tissue ﬁbrosis, both of which may predict LVR (2). sST is a biomarker of inﬂammation, cardiac mechanical strain, and tissue ﬁbrosis(3). B_type natriuretic peptide (BNP) is elevated in acute myocardial infarction and is a quantitative biochemical marker related to the extent of infarction and left ventricular systolic dysfunction(4).

Official Title
-----------------
Diagnostic Values of Galectin-3, Soluble ST2 and BNP in Predicting the Clinical Outcome of ST-Segment Elevation Myocardial Infarction Patients

Conditions
-----------------
ST Elevation Myocardial Infarction, HF - Heart Failure, Stable Angina

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years. Hospital admission due to ﬁrst-time STEMI treated with pPCI. Exclusion Criteria: History of previous acute coronary syndrome, Previously diagnosed HF or asymptomatic LV dysfunction with LVEF <50% or previously diagnosed signiﬁcant valvular disease or any other previously diagnosed structural heart disease Severe renal dysfunction, Severe liver disease, Chronic inﬂammatory disease, Current neoplastic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| STEMI group.<br>60 participants of patients with STEMI treated with primary percutaneous coronary intervention (pPCI). | |
| healthy group.<br>15 participants of healthy people as a case control. | |
| Stable angina group.<br>15 participants of patients stable angina | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| investigate the association of Gal-3, sST2 and BNP concentrations and the development of clinically overt HF in patients after ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention |  | 7 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Galectin-3